EQ
EquilliumDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The constructive case is that March 2026 financing materially reduced near-term solvency pressure and gives EQ504 a funded path into clinic, with management guiding to Phase 1 initiation in mid-2026 and data about six months later [#8-K-2026-03-25] [#10-K-2026-03-25].
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -7.4.
What can break
Additional capital is needed sooner than expected despite runway guidance into 2029.
Momentum
88
Value
41
Sentiment
6
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.40 · Bull $2.60 · Bear $0.80
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $8.56
Why
Momentum88 · Δ7d -7.4
Value41 · Δ7d -0.1
Sentiment6 · Δ7d +0.1
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
88
26% active weight
Current posture
7d trendSoftening
Δ7d
-7.4
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
6
34% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-
Why this grade
Composite grade D. Momentum 88.4 / Value 41.1 / Sentiment 5.6
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$156.17M
Beta
1.87
Shares Out
63.23M
P/E (TTM) · Derived
-6.3
P/S (TTM)
21.77
P/FCF (TTM) · Derived
-8.44
Rev YoY
-100.0%
EPS YoY
-77.3%
Gross Margin
+97.1%
Op Margin
-554.9%
Net Debt
-$29.56M
Current Ratio
18.62
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology